SABCS 2020 | Neratinib, trastuzumab + fulvestrant for HER2-mutant, HR+, metastatic breast cancer

Komal Jhaveri, MD, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the results of the SUMMIT trial (NCT01953926), a Phase II “basket” trial of neratinib, trastuzumab and fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer. In this cohort, the triplet combination resulted in an overall survival rate of 46% and a median progression-free survival of 8.3 months. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).